Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ:BIIB)

181.62 -2.76 (-1.50%)
Streaming Delayed Price Updated: 1:34 PM EDT, Apr 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2
...
15 16 17 18 19 20 21 22 23
...
59 60 Next >
News headline image
Eli Lilly's Donanemab For Alzheimer's Hits FDA Speed Breaker, Biogen Stock Gains On Delayed Decision ↗
The FDA's upcoming advisory committee meeting on Eli Lilly's Phase 3 donanemab trial for early symptomatic Alzheimer's. Understand safety and efficacy considerations, with a delay in expected FDA... 
Via Benzinga
News headline image
FDA Delays Decision On Eli Lilly's Alzheimer Drug ↗
The FDA will hold an advisory panel for Lilly's Alzheimer drug donanemab. 
Via Investor's Business Daily
News headline image
Biogen's Spinraza For Muscle Movement Disorder Shows Improved Motor Function In Infants, Toddlers ↗
Biogen's latest SMA research! Interim data from the RESPOND study reveals promising outcomes with SPINRAZA treatment. Learn about reduced NfL levels and the impact on infants and children with spinal... 
Via Benzinga
News headline image
New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene Therapy
From Biogen Inc.
Via GlobeNewswire
News headline image
A Closer Look at 21 Analyst Recommendations For Biogen ↗
 
Via Benzinga
News headline image
Biogen Unusual Options Activity ↗
 
Via Benzinga
News headline image
Biogen Highlights New Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™) 2024 Annual Meeting
From Biogen Inc.
Via GlobeNewswire
News headline image
Biotechs on the Rise: 3 Stocks to Buy for a Shot of Profits ↗
Given recent industry performance, the enthusiasm investors have for biotech stocks to buy is low. But these three companies seem promising. 
Via InvestorPlace
News headline image
1 Wall Street Analyst Thinks Biogen Stock Is Going to $311. Is It a Buy Around $223? ↗
Getting its Alzheimer's medicine approved in the European Union could be big. 
Via The Motley Fool
News headline image
Top Stocks Not Named Nvidia You Need To Know About In 2024: Here's What Investors Think About Them (Wall Street Vs. Reddit) ↗
Nvidia Corp. is one of the leading top stocks with 60% gain in 2024, but other lesser-known names have outperformed. 
Via Benzinga
News headline image
Peering Into Biogen's Recent Short Interest ↗
 
Via Benzinga
News headline image
BIOGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Biogen Inc. on Behalf of Biogen Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Biogen Inc. (BIIB) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
News headline image
Biogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positive Opinion from CHMP
From Biogen Inc.
Via GlobeNewswire
News headline image
Breaking Down Biogen: 8 Analysts Share Their Views ↗
 
Via Benzinga
News headline image
Biogen Slumps As Aduhelm Costs Squeeze Fourth-Quarter Profit ↗
The company missed both sales and earnings expectations for the fourth quarter. 
Via Investor's Business Daily
News headline image
3 Biotech Stocks to Turn $10,000 Into $1 Million: February 2024 ↗
With new innovation and high demand, biotech stocks could offer some of the most explosive opportunities of the year. 
Via InvestorPlace
News headline image
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Biogen Inc. (BIIB) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
News headline image
The Law Offices of Frank R. Cruz Announces Investigation of Biogen Inc. (BIIB) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
News headline image
From Zero to Hero: 7 Stock Losers That Could Turn Things Around in 2024 ↗
Although these companies suffered earlier, they could become stock turnarounds as investors recognize their potential. 
Via InvestorPlace
News headline image
Looking At Biogen's Recent Unusual Options Activity ↗
 
Via Benzinga
News headline image
7 Contrarian Biotech Stocks to Consider Amid Sector Weakness ↗
Although the healthcare innovation space has struggled recently, these contrarian biotech stocks now offer compelling discounts. 
Via InvestorPlace
News headline image
Biogen Could Engage In $1B-$2B Deals To Fill Revenue Shortfall Gaps, Analyst Says ↗
Biogen's Leqembi launch challenges impact stock growth; Spinraza faces competition. Analyst lowers price target to $316, citing uncertainties. 
Via Benzinga
News headline image
Citigroup To Rally Over 19%? Here Are 10 Top Analyst Forecasts For Wednesday ↗
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
News headline image
Biogen (BIIB) Q4 2023 Earnings Call Transcript ↗
BIIB earnings call for the period ending December 31, 2023. 
Via The Motley Fool
Topics Earnings
News headline image
Markets Tumble, VIX Up 8% On Hot Inflation Data, Dollar, Yields Jump As Traders Unwind Rate Cut Bets: What's Driving Markets Tuesday? ↗
Wall Street witnessed one of the worst sessions since the beginning of the year, with widespread declines across the board as stocks were hit by the impact of a higher-than-expected inflation report. 
Via Benzinga
Topics Economy Stocks
News headline image
Why Is Biogen Stock Trading Lower On Tuesday? ↗
Biogen's Q4 2023 performance, with $2.39 billion in sales, adjusted EPS of $2.95, and updates on key drugs. 
Via Benzinga
News headline image
Nasdaq, S&P 500 Set For Weaker Open As Traders Keep Eyes Peeled On Inflation Data: Analyst Flags Key CPI Report Item To Watch ↗
Despite the Fed rhetoric about the inflation fight being still on, the central bank will likely cut rates this year, an analyst said. 
Via Benzinga
Topics Economy Stocks
News headline image
Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia
From Biogen Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For February 13, 2024 ↗
Companies Reporting Before The Bell • LCI Indus (NYSE:LCII) is likely to report quarterly earnings at $0.18 per share on revenue of $838.27 million. 
Via Benzinga
< Previous 1 2
...
15 16 17 18 19 20 21 22 23
...
59 60 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.